Kolexia
Campone Mario Oncologie médicale
Campone Mario
Oncologie médicale
Ico - Site Paul Papin
Angers, France
793 Activités
4.8 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du sein triple-négatives Récidive tumorale locale Tumeurs du cerveau Glioblastome Carcinomes Cellules tumorales circulantes Tumeurs osseuses

Collaborateurs

Voir plus
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Andre Fabrice
Andre Fabrice
Gustave-Roussy, Villejuif, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Frenel Jean-Sebastien
Frenel Jean-Sebastien
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
Daiichi Sankyo
24 collaboration(s)
Dernière en 2023
Lilly
22 collaboration(s)
Dernière en 2023
Novartis
14 collaboration(s)
Dernière en 2023
Pfizer
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Essai Clinique (Lilly)   16 mars 2024
MONARCH 3: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting
Essai Clinique (Lilly)   15 mars 2024
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Essai Clinique (Lilly)   11 mars 2024
POPCASE: Prospective, Multicenter, Epidemiological Case-control Study, to Establish a Possible Correlation Between Persistent Chemical Contaminants (POPs) and Breast Cancer.
Essai Clinique (Institut Cancerologie de l'Ouest)   11 mars 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer: A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Essai Clinique (Abbvie)   19 février 2024
AMEERA-1: A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of Amcenestrant (SAR439859), Administered Orally as Monotherapy, Then in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer
Essai Clinique (Sanofi)   08 février 2024
Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE): Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting
Essai Clinique (Institut Curie)   29 janvier 2024
Open Label Clinical Trial of Intravenous Crotoxin Part 3: Open Label Phase I Clinical Trial of Crotoxin in Patients With Advanced Cancer Using an Intravenous Route of Administration
Essai Clinique (Celtic Biotech Ltd)   13 janvier 2024